Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis (Q37848117)

24 August 2017

1 reference

title

Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis (English)

1 reference

24 August 2017

1 reference

2

1 reference

24 August 2017

Carlo A Marra

1

1 reference

24 August 2017

Aslam H Anis

series ordinal

3

1 reference

24 August 2017

Kamran Shojania

series ordinal

4

1 reference

24 August 2017

publication date

26 February 2011

1 reference

24 August 2017

published in

Clinical Rheumatology

1 reference

24 August 2017

volume

30 Suppl 1

1 reference

24 August 2017

page(s)

S9-18

1 reference

Modelling in economic evaluation: an unavoidable fact of life

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Whither trial-based economic evaluation for health care decision making?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Modelling in the economic evaluation of health care: selecting the appropriate approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Health economic evaluation: a primer for the practicing rheumatologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Cost-effectiveness analysis of biological treatments for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Not all "quality-adjusted life years" are equal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmö, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Limited correlation between the Health Assessment Questionnaire (HAQ) and EuroQol in rheumatoid arthritis: questionable validity of deriving quality adjusted life years from HAQ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Predicting mortality in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

The costs of rheumatoid arthritis: an international long-term view

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Biologic drugs for rheumatoid arthritis in the medicare program: A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1635-8

Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis

21 January 2018

1 reference

12 December 2020

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

1 reference

12 December 2020

The psychometrics of functional status questionnaires: room for improvement

1 reference

12 December 2020

Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire

1 reference

12 December 2020

A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis

1 reference

12 December 2020

Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis

1 reference

12 December 2020

Do rheumatology cost-effectiveness analyses make sense?

1 reference

12 December 2020

The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work

1 reference

12 December 2020

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis

1 reference

12 December 2020

Rituximab for rheumatoid arthritis

1 reference

12 December 2020

Review of health economics modelling in rheumatoid arthritis

1 reference

12 December 2020

A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis

1 reference

12 December 2020

Cost-effectiveness analysis: out of touch with clinical reality?

1 reference

12 December 2020

Epidemiology and burden of illness of rheumatoid arthritis

1 reference

12 December 2020

Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists

1 reference

12 December 2020

UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

1 reference

12 December 2020

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes

1 reference

12 December 2020

Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis

1 reference

12 December 2020

The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study

1 reference

12 December 2020

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.

1 reference

12 December 2020

The effects of rheumatoid arthritis on labor force participation, work performance, and healthcare costs in two workplace samples

1 reference

12 December 2020

10.1007/S10067-010-1635-8

Identifiers

DOI

1 reference

24 August 2017

1 reference